Blog Archives

ImmuPharma’s Lupuzor fails to meet the primary endpoint in its phase 3 trial

I woke to extremely disappointing news this morning. In my Hope for 2016 post, I mentioned peptide based drugs as my #2 hope, with Lupuzor being the key candidate. Over the past several years, I have watched the Lupuzor trials

Posted in Clinical Trials, Treatment Tagged with: ,
WordPress Appliance - Powered by TurnKey Linux